FDA 483 - Tens Plus Industrial Co. - November 21, 2024

This summary is illustrative as the provided document content (pages 10-16 of 20) was missing. Had content been available, this section would present a concise overview. Typically, an FDA Form 483 outlines observations made during an inspection of a regulated facility. Such a summary would detail the company name, the specific dates of the inspection, and the main violations or issues identified by the FDA investigator. These issues often relate to non-compliance with current Good Manufacturing Practices (cGMP) under the regulatory framework of 21 CFR Parts 210/211 for pharmaceuticals, or similar regulations for medical devices. Common observations might include inadequate quality control procedures, deficiencies in equipment maintenance, insufficient investigation into product deviations, or issues with documentation. The summary would conclude by noting that the company is required to submit a comprehensive response addressing each observation with proposed corrective and preventive actions to ensure compliance.